Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
Go back to Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule| (NASDAQ: HELP) | Delayed: 7.78 -0.04 (0.51%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.82 | 52 Week High | $ | |||
| Open | $7.78 | 52 Week Low | $ | |||
| Day High | $8.16 | P/E | N/A | |||
| Day Low | $7.67 | EPS | $ | |||
| Volume | 671,856 | |||||
